Literature DB >> 12518709

Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole.

Angela Abelö1, Björn Holstein, Ulf G Eriksson, Johan Gabrielsson, Mats O Karlsson.   

Abstract

A mechanism-based pharmacodynamic model was used to describe the inhibitory effect by omeprazole on gastric acid secretion measured after histamine stimulation in the dog. The model identifies parameters that are related to the physiological system, the histamine stimulation, and the irreversible effect of omeprazole on the H+, K(+)-ATPase enzyme. Four different experiments with omeprazole (Exps. 1-4) and two placebo experiments were performed in each of the four Heidenhain pouch dogs used. For placebo and experiments 1-3, saline or omeprazole 0.81 mumol/kg was infused during 3 hr with measurements of histamine-stimulated gastric acid secretion in two periods of 3.5-6.5 hr, one period starting just before the omeprazole infusion and a second later period up to 29 hr post infusion. In experiment 4, 0.18 mumol/kg of omeprazole was infused for 22.5 min and gastric juice was collected for 5 hr post infusion. The response data was well described by the model. Similar parameter estimates were obtained by three different analysis methods; naïve pooling, two-stage method and nonlinear mixed effects modeling. The elimination rate constant for the H+, K(+)-ATPase enzyme, kout, was estimated to be 0.040 hr-1, corresponding to a half-life of about 17 hr. This rate constant determines the duration of omeprazole inhibition after long-term exposure. For short-term omeprazole exposure the duration is determined by the rate constant for transfer of enzymes from active to resting state, estimated to be 1.88 hr-1. The second-order rate constant for histamine stimulation was estimated to be 0.064 hr-1 per histamine concentration unit and the maximum acid secretion was estimated to be 5.0 mmol H+/30 min. The second-order rate constant for the irreversible binding of omeprazole to H+, K(+)-ATPase, kome, was estimated to be 2.39 L/mumol.hr. By modeling the histamine-induced baseline response simultaneously with active treatment, predictions of the response are possible not only following different dosing regimens of omeprazole, but also following different degrees of histamine stimulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12518709     DOI: 10.1023/a:1020905224001

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  21 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  The distribution and fate of radioactive histamine in the rat.

Authors:  B N HALPERN; T NEVEU; C W WILSON
Journal:  J Physiol       Date:  1959-10       Impact factor: 5.182

Review 3.  Gastric acid secretion.

Authors:  S J Hersey; G Sachs
Journal:  Physiol Rev       Date:  1995-01       Impact factor: 37.312

4.  Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transport.

Authors:  P Lorentzon; R Jackson; B Wallmark; G Sachs
Journal:  Biochim Biophys Acta       Date:  1987-02-12

5.  The specificity of omeprazole as an (H+ + K+)-ATPase inhibitor depends upon the means of its activation.

Authors:  D J Keeling; C Fallowfield; A H Underwood
Journal:  Biochem Pharmacol       Date:  1987-02-01       Impact factor: 5.858

6.  The pharmacokinetics of propofol in children using three different data analysis approaches.

Authors:  B K Kataria; S A Ved; H F Nicodemus; G R Hoy; D Lea; M Y Dubois; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1994-01       Impact factor: 7.892

7.  A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.

Authors:  P O Gisleskog; D Hermann; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  1998-12       Impact factor: 6.875

8.  Inhibition of gastric acid secretion by omeprazole in the dog and rat.

Authors:  H Larsson; E Carlsson; U Junggren; L Olbe; S E Sjöstrand; I Skånberg; G Sundell
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

9.  Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

Authors:  P O Lagerström; B A Persson
Journal:  J Chromatogr       Date:  1984-08-10

10.  Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.

Authors:  M Katashima; K Yamamoto; Y Tokuma; T Hata; Y Sawada; T Iga
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.569

View more
  7 in total

Review 1.  Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics.

Authors:  Fereidoon Daryaee; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2019-04-28       Impact factor: 8.822

2.  Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler.

Authors:  Xiaoxi Liu; Bridgette L Jones; Jessica K Roberts; Catherine M Sherwin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-06-15       Impact factor: 2.745

3.  Efficacy of intravenous administration of combined acid suppressants in healthy dogs.

Authors:  M K Tolbert; A Odunayo; R S Howell; E E Peters; A Reed
Journal:  J Vet Intern Med       Date:  2015-02-25       Impact factor: 3.333

Review 4.  Multi-scale modeling of drug binding kinetics to predict drug efficacy.

Authors:  Fabrizio Clarelli; Jingyi Liang; Antal Martinecz; Ines Heiland; Pia Abel Zur Wiesch
Journal:  Cell Mol Life Sci       Date:  2019-11-25       Impact factor: 9.261

5.  Evaluation of proton pump inhibitor administration in hospitalized dogs in a tertiary referral hospital.

Authors:  Samantha Duxbury; Emily Sorah; M Katherine Tolbert
Journal:  J Vet Intern Med       Date:  2022-07-22       Impact factor: 3.175

6.  Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

Authors:  Wilhelmus E A de Witte; Vivi Rottschäfer; Meindert Danhof; Piet H van der Graaf; Lambertus A Peletier; Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-18       Impact factor: 2.745

7.  ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.

Authors:  Stanley L Marks; Peter H Kook; Mark G Papich; M K Tolbert; Michael D Willard
Journal:  J Vet Intern Med       Date:  2018-10-31       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.